Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis - 21/08/11
Doi : 10.1016/j.jaad.2004.05.044
Uma Nadiminti, MD, Jack L. Arbiser, MD, PhD ⁎ 
From the Department of Dermatology, Emory University School of Medicine, and Atlanta Department of Veterans Affairs Medical Center
Reprint requests: Jack L. Arbiser, MD, PhD, Department of Dermatology, Emory University School of Medicine, WMB 5309, 1639 Pierce Dr, Atlanta, GA 30322.Atlanta, Georgia
Abstract |
Dermatomyositis is an autoimmune condition that results in significant morbidity and mortality through effects on muscle and skin. Corticosteroids are the mainstay of therapy of dermatomyositis, and severe morbidity and mortality occurs in part through the known long-term side effects of chronic steroid use. In addition, dermatomyositis is commonly associated with underlying malignancy, and high-dose steroids may adversely impair treatment of these malignancies. We describe the first use of rapamycin in a young patient with dermatomyositis.
Le texte complet de cet article est disponible en PDF.Plan
| This supplement is made possible through the generous support of Stiefel Laboratories for the American Academy of Dermatology. Funding sources: None. Conflicts of interest: None identified. |
© 2005
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 52 - N° 2S
P. S17-S19 - février 2005 Retour au numéro
Article précédent
- Chronic telogen effluvium: A study of 5 patients over 7 years
- Rodney Sinclair
- Treatment of scalp angiosarcoma by controlled perfusion of A. carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa
- Anne B. Bong, Bernd Bonnekoh, Michael Peter Schön, Harald Gollnick
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?